Screener
Celldex Therapeutics CLDX Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's other non-current liabilities?
- Celldex Therapeutics (CLDX) reported other non-current liabilities of $3.11M in Q2 2026.
- How has Celldex Therapeutics's other non-current liabilities changed year-over-year?
- Celldex Therapeutics's other non-current liabilities increased by 22.4% year-over-year, from $2.54M to $3.11M.
- What is the long-term trend for Celldex Therapeutics's other non-current liabilities?
- Over 5 years (2020 to 2025), Celldex Therapeutics's other non-current liabilities has grown at a -16.8% compound annual growth rate (CAGR), from $10.12M to $4.04M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Celldex Therapeutics's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude